Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

Spine

IDENTIFYING TREATMENT EFFECT MODIFIERS IN THE START BACK TRIAL: A SECONDARY ANALYSIS

The Society for Back Pain Research (SBPR) - Annual General Meeting 2015



Abstract

Purpose and Background:

To identify treatment effect modifiers within the STarT Back Trial which demonstrated prognostic stratified care was effective in comparison to standard care for patients with low back pain.

Methods:

Secondary analysis of the STarT Back Trial using 688 patients with available 4-month follow-up data. Disability (baseline and 4 months) was assessed using the Roland Morris Disability Questionnaire (RMDQ) using continuous and dichotomized (>7) outcome scores. Potential treatment effect modifiers were evaluated with group x predictor interaction terms using linear and logistic regression models. Modifiers included: age, gender, education, socio-economic status (SES), employment status, work satisfaction, episode duration, general health (SF-12), number of pain medications, and treatment expectations.

Results:

No significant treatment effect modifiers were identified using linear regression, however logistic regression analysis identified SES as a treatment modifier (interaction: OR = 0.65; 95% confidence interval = 0.42 to 0.98). Comparing those receiving stratified care versus best current care, the proportion of patients with poor 4 month outcome was similar for lower SES patients (35.4% vs. 37.2%), yet different for high SES patients (19.3% vs. 38.9%). No other treatment effect modifiers were identified; however exploratory analyses indicated trends for worse outcomes with increased age, patients taking ≥3 medications, those with lower education, and those with poor treatment expectations as potential treatment effect modifiers.

Conclusion:

SES was identified as a treatment effect modifier in the STarT Back Trial with patients with lower SES not benefiting from stratified care. The explanations for this finding need further exploration.


Email:

Conflicts of interest: None

Sources of funding: Jason Beneciuk was supported by the American National Institutes of Health (NIH) Rehabilitation Research Career Development Program (K12-HD055929). Nadine Foster is supported through a UK National Institute for Health Research (NIHR) Research Professorship (NIHR-RP-011-015). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIH, the NIHR or the Department of Health.